Covid variant tracking
The SARS-CoV-2 virus is the most sequenced organism on Earth, allowing scientists to quickly spot new variants as they spread.

Key players
GISAID, Nextstrain, Illumina
Availability
Now
Among all the nose swabs that have ever come up positive for covid-19 over the course of the pandemic, about two in a hundred have been sent for extra analysis in a gene sequencing machine. The objective: to create a fresh map of the SARS-CoV-2 virus’s genome—all 30,000 or so letters—and see what’s changed.
Such genetic surveillance has allowed scientists to quickly spot and warn about new variants like alpha, delta, and mostly recently omicron. It’s an unprecedented effort that’s turned SARS-CoV-2 into history’s most sequenced organism—blasting past the flu, HIV, or even our own human genome. Open databases now display more than 7 million maps of the germ’s genes.
Omicron is the most dramatic evolution yet. A lab in South Africa first sent up a warning flare in November after its sequencers spotted a virus genome with more than 50 mutations. Almost instantly, computers in Seattle, Boston, and London were using the data to spit out predictions: omicron was trouble, a variant likely to evade antibodies.
One thing the sequencers can’t yet tell us is how, exactly, SARS-CoV-2 will evolve next. That’s why some say we should be tracking the germ even more closely. The majority of sequences are being generated in places like the UK, the US, and Denmark. But the virus can still evolve, unwitnessed, in regions without the capacity to sequence. Luckily, the quick work in South Africa to spot omicron and track its spread gave the world an early warning.
As part of our 10 Breakthrough Technologies series, meet the scientist who warned the world about omicron.
CORRECTION: GISAID is an organization that promotes rapid sharing of flu and coronavirus genetic data and Nextstrain is a project developing software for analyzing such data. An earlier version of this article incorrectly referred to both as databases.
Deep Dive
Biotechnology and health
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
A biotech company says it put dopamine-making cells into people’s brains
The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.
Tiny faux organs could crack the mystery of menstruation
Researchers are using organoids to unlock one of the human body’s most mysterious—and miraculous—processes.
After 25 years of hype, embryonic stem cells are still waiting for their moment
Research roadblocks and political debates have delayed progress—but scientists are inching closer to delivering a cure.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.